Core Viewpoint - Kingsray Biotechnology (01548) announced that CARVYKTI® is projected to generate trade sales net revenue of approximately $524 million for the quarter ending September 30, 2025, based on the collaboration and licensing agreement established with Janssen Biotech, Inc. on December 21, 2017 [1] Summary by Category - **Company Performance** - CARVYKTI® is expected to achieve net trade sales of about $524 million by the end of Q3 2025 [1] - **Partnerships** - The revenue projection is based on the collaboration and licensing agreement with Janssen Biotech, Inc. signed on December 21, 2017 [1]

Core Viewpoint - Kingsray Biotechnology (01548) announced that CARVYKTI is expected to generate net trade sales of approximately $524 million for the quarter ending September 30, 2025, based on the collaboration and licensing agreement established with Janssen Biotech, Inc. on December 21, 2017 [1] Group 1 - Kingsray Biotechnology has a collaboration and licensing agreement with Janssen Biotech, Inc. [1] - The projected net trade sales for CARVYKTI are approximately $524 million for the quarter ending September 30, 2025 [1]

Company News - China Metallurgical Group Corporation (01618.HK) reported a new contract amount of 760.67 billion yuan for the first nine months, a year-on-year decrease of 14.7%. The overseas contract amount was 66.9 billion yuan, showing a year-on-year increase of 10.1% [1] - China General Nuclear Power Corporation (01816.HK) achieved a total power generation of approximately 182.822 billion kWh in the first nine months, representing a year-on-year growth of 2.67% [1] - "Jiao Ge Peng You" Holdings (01450.HK) recorded a cumulative GMV of approximately 9.53 billion yuan for the first three quarters, a year-on-year increase of 7.56%. However, the GMV for the third quarter was about 2.55 billion yuan, reflecting a year-on-year decline of approximately 12.07% [1] - China Resources Land (01109.HK) reported a cumulative contract sales amount of approximately 154.4 billion yuan for the first nine months, a year-on-year decrease of 10.4% [1] - Times China Holdings (01233.HK) reported cumulative contract sales of 3.933 billion yuan for the first nine months, a year-on-year decline of 37.1% [1] - ZhongAn Online P&C Insurance (06060.HK) achieved cumulative original insurance premium income of 26.934 billion yuan in the first nine months, a year-on-year increase of 5.64% [1] - COFCO Joycome (01610.HK) reported a pig slaughter volume of 468,000 heads in September, a month-on-month decrease of 6.02% [1] - Kingsoft Cloud Holdings (01548.HK) received a new payment under a licensing agreement related to PD-1 monoclonal antibodies, which will enhance cash reserves for new molecular discovery and development [2] - China National Building Material Group (03323.HK) expects a net profit of 2.95 billion yuan for the first three quarters, turning from loss to profit, mainly due to a decrease in sales costs of cement and ready-mixed concrete [2] - Lifen Holdings (01125.HK) issued a profit warning, expecting a year-on-year increase of no less than 50% in annual losses attributable to owners [2] - China Property Investment (00736.HK) signed a cooperation framework agreement to tokenize high-quality photovoltaic new energy assets [2] - Dali Pu Holdings (01921.HK) established a direct sales warehouse and sales office in Oman to strengthen its strategic layout in the Middle East [2] - Beijing Machinery Electric Co., Ltd. (00187.HK) faced bankruptcy liquidation application from creditors for its subsidiary Tianhai Cryogenic [2] Financing and Buyback Activities - Jihai Resources (02489.HK) successfully placed 400 million shares at 1.18 HKD per share, raising approximately 466 million HKD for potential gold mine acquisitions and general working capital [2] - China Galaxy Securities (06881.HK) was approved to issue short-term corporate bonds not exceeding 15 billion yuan [3] - Kuaishou Technology (01024.HK) repurchased 1.3146 million shares for approximately 98.4067 million HKD at prices ranging from 74.55 to 75.1 HKD [3] - Xiaomi Group (01810.HK) repurchased 4 million shares for approximately 19.5 million HKD at prices ranging from 48.44 to 49 HKD [4]

Core Insights - Kingsray Biotechnology (01548) announced that CARVYKTI® is expected to generate net trade sales of approximately $524 million for the quarter ending September 30, 2025, based on the collaboration and licensing agreement established with Legend and Janssen Biotech, Inc. on December 21, 2017 [1] Group 1 - Kingsray Biotechnology's CARVYKTI® is projected to achieve significant sales figures, indicating strong market potential [1] - The collaboration with Janssen Biotech, Inc. highlights strategic partnerships in the biotechnology sector [1] - The timeline for the projected sales extends to the end of Q3 2025, suggesting a long-term outlook for revenue generation [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Genscript Biotech Corporation （於開曼群島註冊成立的有限公司） （股份代號：1548） 自願性公告 傳奇宣佈截至2025年9月30日止季度 CARVYKTI®的初步銷售額 本公告以英文發佈，並附有中文翻譯。如中英文版本有任何不一致或歧義，應以英文 版為准。 本公司股東及潛在投資者務請注意投資風險，並於買賣或擬買賣本公司證券時審慎行 事。 承董事會命 Genscript Biotech Corporation 孟建革 主席及執行董事 關於前瞻性陳述的警示性說明 本公告中關於未來預期、計劃和前景的陳述，以及關於非歷史事實事項的任何其他陳 述，均構成《1995年私人證券訴訟改革法案》所界定的「前瞻性陳述」。這些陳述包 括但不限於與CARVYKTI®有關的陳述，包括傳奇對CARVYKTI®貿易銷售淨額和由此 產生的毛利的預期。「預期」、「相信」、「繼續」、「可能」、「估計」、「期 望 ...

Core Viewpoint - Kingsray Biotechnology (01548.HK) announced a new payment of approximately RMB 479.7 million (about USD 67.5 million after tax deductions) related to a revised licensing agreement for an anti-PD-1 single-domain antibody, which is linked to the development of the dual-specific antibody LM-299 that has received clinical research approval [1] Group 1 - The payment represents the second installment of licensing revenue associated with the anti-PD-1 single-domain antibody [1] - Cumulatively, Kingsray has received approximately RMB 2 billion (about USD 283.6 million after tax deductions) under the revised licensing agreement as of October 14, 2025 [1] - The incoming funds will enhance Kingsray's cash reserves and support new molecular discovery and development [1] Group 2 - The licensed anti-PD-1 single-domain antibody demonstrates high efficiency and specificity in binding to human and cynomolgus monkey PD1, effectively blocking PD1/PD-L1 integration [1] - In rodent efficacy models, the antibody has shown tumor growth inhibition comparable to Merck's Keytruda, along with ideal CMC (Chemistry, Manufacturing, and Control) drug-like properties [1]

Core Insights - Kingsray Biotechnology (01548) announced the receipt of approximately RMB 480 million (around USD 67.5 million, net of withholding tax) as a new payment under the restated and amended licensing agreement [1] - This payment represents the second tranche of sublicensing revenue related to the licensed anti-PD-1 single-domain antibody, which is utilized in the development of the investigational PD-1/VEGF bispecific antibody LM-299, now approved for new drug clinical research [1] - As of October 14, 2025, Kingsray has cumulatively received approximately RMB 2 billion (around USD 284 million, net of withholding tax) under the same licensing agreement [1] - The incoming funds will further enhance Kingsray's cash reserves and support new molecular discovery and development [1]

Core Viewpoint - Kingsray Biotechnology (01548) announced the receipt of approximately RMB 480 million (around USD 67.5 million, net of withholding tax) as the second payment under a revised licensing agreement related to an anti-PD-1 single-domain antibody [1] Group 1: Financial Impact - The payment is part of the licensing income associated with the anti-PD-1 single-domain antibody used in the development of the dual-specific antibody LM-299, which has received clinical research approval [1] - As of October 14, 2025, Kingsray has cumulatively received approximately RMB 2 billion (around USD 284 million, net of withholding tax) under the revised licensing agreement [1] Group 2: Strategic Use of Funds - The incoming funds will enhance Kingsray's cash reserves and will be utilized to support new molecular discovery and development [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任 何損失承擔任何責任。 Genscript Biotech Corporation （於開曼群島註冊成立的有限公司） （股份代號：1548） 内幕消息公告 根據與禮新醫藥科技有限公司的許可協議 蓬勃收到付款 本公告由金斯瑞生物科技股份有限公司（「本公司」，連同其附屬公司，稱爲「本集團」） 董事會（「董事會」）根據香港聯合交易所有限公司證券上市規則第 13.09 條與香港法例 第 571 章證券及期貨條例第 XIVA 部內幕消息條文（定義見上市規則）而作出。 兹提述本公司日期爲 2024 年 11 月 15 日及 2025 年 6 月 30 日的公告，內容有關南京蓬勃和 禮新訂立的經重述及經修訂許可協議（根據該協議，南京蓬勃同意授予禮新（其中包括） 一项獨家全球可轉讓許可（包含分許可權），許可專利披露抗 PD-1 單域抗體和相關專有 技術，由此禮新可針對許可專利進行開發、生產、商業化及以其他方式應用許可產品，以 用於全球所有用途 ...

Core Viewpoint - The Hong Kong biopharmaceutical sector experienced a significant decline, with major companies reporting substantial drops in stock prices, indicating a bearish trend in the market [1]. Group 1: Stock Performance - Innovent Biologics (099660) saw a decline of 11.54%, with a latest price of 16.640 and a market capitalization of 293.36 billion, despite a year-to-date increase of 171.90% [2]. - Rongchang Biologics (09995) dropped by 9.20%, priced at 108.600, with a total market value of 612.08 billion, and a remarkable year-to-date increase of 654.17% [2]. - Kelun-Biotech (06990) fell by 7.71%, with a latest price of 533.000 and a market cap of 1,242.88 billion, while still showing a year-to-date increase of 226.39% [2]. - Tigermed (03347) decreased by 6.86%, priced at 43.960, with a market capitalization of 378.51 billion and a year-to-date increase of 44.25% [2]. - WuXi AppTec (02268) experienced a decline of 6.22%, with a latest price of 77.650 and a market cap of 954.09 billion, maintaining a year-to-date increase of 153.34% [2]. - CanSino Biologics (09926) dropped by 5.15%, priced at 134.500, with a market capitalization of 1,238.94 billion, and a year-to-date increase of 121.58% [2]. - Other companies like Junshi Biosciences (01877) and BeiGene (06160) also reported declines, with respective decreases of 3.16% and 2.48% [2].